PURMINDS
DEAD

Serial Number

97978391

Owner

PurMinds Biopharma Inc.

Attorney

Philip L. Conrad

Filing Date

Nov 3, 2021

Add to watchlist:

No watchlists yet
View on USPTO

PURMINDS Trademark

Serial Number: 97978391

PURMINDS is a trademark filed by PurMinds Biopharma Inc. on November 3, 2021. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently no longer active.

Owner Contact Info

PurMinds Biopharma Inc. (2 trademarks)

10 Loring Drive
Bolton, Ontario L7E1J9 , CA

Entity Type: 03

Trademark Details

Filing Date

November 3, 2021

Registration Date

Not Registered

Published for Opposition

July 16, 2024

Goods & Services

Analyzing statistical neuroinformatic health data generated through the drug discovery process in order to uncover and identify health care fraud and claims errors

Downloadable computer software programs for database management in the biotechnology field, namely, software for creating and visualizing in-silico models of biological systems, in particular 3D models of human and brain cells, and to generate new data to detail, predict and modulate complex molecular mechanisms and interactions with the systems and network levels; Downloadable software programs using artificial intelligence and machine learning for data analysis, data screening, and data processing in the fields of computational biology, In Silico experiments, robotic Microscopy, molecular assembler, brain-computer interface, bioinformatics, and neuroinformatics, to develop predictive models to accelerate drug discovery; Downloadable software applications using artificial intelligence and machine learning for data analysis for scientific and pharmaceutical product development and research purposes; downloadable software application for use in collecting and analyzing data related to neurological disorders, neurodegenerative diseases, Alzheimer's disease, and bioinformatics

Research and development of prescriptions pharmaceutical preparations for the prevention and treatment of neurological disorders and neurodegenerative diseases, and Alzheimer's disease; Research and development of a portfolio of psychotropics, psychoactive compounds and non-psychoactive compounds and molecules for the prevention and treatment of neurological disorders and neurodegenerative diseases, and Alzheimer's disease; Laboratory analysis in the field of psychoactive drugs; Clinical laboratory testing and toxicology service, namely, molecular and endocrinology chemical analysis; medical laboratory services; laboratory testing in the nature of laboratory analysis of biologic substances for metals, occupational, and environmental toxins; Providing on-line non-downloadable software for machine learning in the fields of generating in-silico simulations of physiological responses for scientific, pharmaceutical research, product development, and educational purposes; Engineering and technical assistance in the nature of computer software consultation in the field of computer software that provides dynamic simulations of physiology for scientific, pharmaceutical research, product development, and educational purposes; Software design, engineering, and development services in the fields of artificial intelligence, machine learning, computational biology, In Silico analyses and screening, robotic Microscopy, molecular assembler, brain-computer interface, bioinformatics, neuroinformatic and consultation services related thereto

Providing medical information, consultancy and advisory services related to the treatment of neurological disorders, neurodegenerative diseases, and Alzheimer's disease; Providing information about health and wellness, namely, in the field of psychotropics, psychoactive compounds and non-psychoactive compounds and molecules; Clinical therapeutic drug monitoring, in the nature of drug use screening services for medical purposes; Medical screening and analytical services in the neuroscience field relating to the treatment of persons; remote monitoring of neuroinformatic medical data and algorithms generated through the drug discovery process for medical diagnosis and treatment

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Apr 14, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 14, 2025 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 10, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 16, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 16, 2024 PUBO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 16, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 16, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 26, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 7, 2024 CNSA
DIVISIONAL PROCESSING COMPLETE
Jun 6, 2024 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 6, 2024 AITU
DIVISIONAL REQUEST RECEIVED
Jun 5, 2024 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Jun 5, 2024 ERTD
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 5, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 5, 2024 ERFR
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jun 5, 2024 JURT
EX PARTE APPEAL-INSTITUTED
Jun 5, 2024 EXPI
EXPARTE APPEAL RECEIVED AT TTAB
Jun 5, 2024 EXAF
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 22, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 22, 2024 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 5, 2023 GNFN
FINAL REFUSAL E-MAILED
Dec 5, 2023 GNFR
FINAL REFUSAL WRITTEN
Dec 5, 2023 CNFR
ASSIGNED TO EXAMINER
Nov 7, 2023 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 27, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 26, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 26, 2023 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 26, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 26, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 26, 2023 REAP
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 25, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 25, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 26, 2023 GNRN
NON-FINAL ACTION E-MAILED
Apr 26, 2023 GNRT
NON-FINAL ACTION WRITTEN
Apr 26, 2023 CNRT
ASSIGNED TO EXAMINER
Apr 10, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 13, 2021 NWOS
NEW APPLICATION ENTERED
Nov 6, 2021 NWAP